Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biodesix (BDSX) Total Current Liabilities (2019 - 2025)

Historic Total Current Liabilities for Biodesix (BDSX) over the last 7 years, with Q3 2025 value amounting to $18.2 million.

  • Biodesix's Total Current Liabilities rose 4002.93% to $18.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $18.2 million, marking a year-over-year increase of 4002.93%. This contributed to the annual value of $14.3 million for FY2024, which is 5715.53% down from last year.
  • Biodesix's Total Current Liabilities amounted to $18.2 million in Q3 2025, which was up 4002.93% from $15.2 million recorded in Q2 2025.
  • In the past 5 years, Biodesix's Total Current Liabilities ranged from a high of $37.4 million in Q3 2022 and a low of $13.0 million during Q3 2024
  • Its 5-year average for Total Current Liabilities is $23.7 million, with a median of $22.8 million in 2021.
  • Per our database at Business Quant, Biodesix's Total Current Liabilities soared by 8488.59% in 2022 and then plummeted by 6029.59% in 2024.
  • Biodesix's Total Current Liabilities (Quarter) stood at $29.0 million in 2021, then decreased by 21.14% to $22.8 million in 2022, then surged by 46.31% to $33.4 million in 2023, then tumbled by 57.16% to $14.3 million in 2024, then increased by 26.79% to $18.2 million in 2025.
  • Its Total Current Liabilities was $18.2 million in Q3 2025, compared to $15.2 million in Q2 2025 and $13.3 million in Q1 2025.